AHCDC PRACTICE guidelines
- Hemophiila and von
Willebrand's Disease.
1. Diagnosis comprehensive care and assessment (Edition 2, update 2 [1997-07-07])
- Hemophilia
and von Willebrand's Disease.
2. Management (Edition 2, update 2 [1997-07-07])
- Suggestions
for the Management of Hemophiliacs and non-hemophiliacs
with Factor VIII Inhibitors (Edition 3, [1999-05-14])
- Standards
of Care from the Standards of Care Conference, Winnipeg, MB,
April 30-May 2, 1998
AHCDC PUBLICATIONS
- Canadian Hemophilia Registry - Operating Guidelines (revised 2005) PDF
- Canadian Comprehensive care Standards for Hemophilia and other Inherited Bleeding Disorders (First Edition 2007)
AHCDC JOINT PUBLICATIONS
2008- Publications
1. Biss, T.T., Chan, A.K., Blanchette, V.S., Iwenofu,L.N., McLimont, M. and Carcao, M.D. for the Association of Hemophilia Clinic Directors of Canada (AHCDC) and the Canadian Association of Nurses in Hemophilia Care (CANHC) (including Poon, M-C). The use of prophylaxis in 2663 children and audlts with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia, 14:923-930, 2008
2.
Bowen, T., Cicardi, M., Bork,K., Zuraw, B., Frank, M., Ritchie,
B., Farkas, H., Varga, L., ] Zingale, L.C., Binkley, K., Wagner, E.,
3.
Hull, R.D., Pineo, G.F., Rant, R., Liang, J., Cook, R., Solymoss,
S., Poon, M-C., Raskob, G. for the LITE Trial Investigators. Home treatment
with long-term low molecular weight heparin (tinzaparin) versus usual care oral
anticoagulation for proximal vein thrombosis: efficacy, safety and impact on
patient satisfaction and the post-thrombotic syndrome. American Journal of Medicine (in press)
4.
Jackson, S., Beck, P., Buret, A.G., O’Conner, P.M., Meddings, J.,
5.
Jackson, S.C., Sinclair, G.D., Cloutier, S., Duan, Z., Rand, M.L.
6.
Moltzan, C.J., Anderson, D.A., Callum, J., Fremes, S., Hume, H.,
Mazer, D., Poon, M-C., Rivard, G., Rizoli, S. and Robinson, S. The evidence for
the use of recombinant factor VIIa in massive bleeding: development of a
transfusion policy framework. Transfusion Medicine, 18: 112–120, 2008
7.
Owen, C.J., Toze, C.L., Koochin, A., Forrest, D.L., Smith, C.A.,
8. Préhu, C., Balamitsa, V., Moradkani, K., Luo, H.-Y., Poon, M-C., Chui, D.H., Wajcman, H. and Patrinos, G.P. Mutations in gene paralogues yielding an identical protein: Functional and evolutionary implications. American Journal of Hematology (in press)
9.
10.
Rubinger, M., Lillicrap, D., Rivard, G.E., Teitel, J., Carcao, M.,
Hensman, C., Walker, I. and the Association of Hemophilia Clinic Directors of
Canada (AHCDC) (including Poon, M-C.) A prospective surveillance study of
factor VIII inhibitor development in the Canadian haemophilia A population
following the switch to a recombinant factor VIII product formulated with
sucrose. Haemophilia. (2); 14: 281-286, 2008
11. Schulman, S., Eelde, A., Holmstrom, M., Stahlberg, G., Odeberg, J., Blombacks, M. Validation of a composite score for clinical severity of hemophilia. Journal of Thrombosis and Haemostasis, 2008, 6: 1113-1121
12. Stonebraker, J.S., Bolton-Maggs, P.H.B., Soucie, J., Walker, I., Brooker, M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia, 2010, 16, 20-32.
13.
Teitel, J.M., Carcao, M., Lillicrap, D., Mulder, K., Rivard, G.E.,
St-Louis, J., Smith, F., Walker, I., Zourikian, N. Orthopaedic surgery in
haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Hemophilia 2009, 15, 227-239
2007 and prior Publications
- A founder von Willebrand factor haplotype
association with type 1 von Willebrand disease. On 20
March 2003 an epublication on Blood first edition on line site.
- AHCDC (Association of Hemophilia Clinic Directors of
Canada) Hemophilia And Von Willebrands
disease: 1. Diagnosis, comprehensive care and assessment. CMAJ 1995;153:19-25.
- AHCDC (Association of Hemophilia Clinic Directors of
Canada) Hemophilia And Von Willebrands disease: 2.
Management. CMAJ 1995;153:147-57.
- Arnold D.M, Julian J.A. and Walker I.R, for the Association
of Hemophilia Clinic Directors of Canada. Mortality
rates and causes of death among all HIV-positive individuals with
hemophilia in Canada over 21 years of follow-up. Blood, 15
July 2006, Volume 108, Number 2, pages 460-464
- Arnold E, Heddle N, Lane S, Sek J, Almonte T, Walker
I. Handheld computers and paper diaries for documenting the
use
of factor concentrates used in haemophilia home therapy: a qualitative
study. Haemophilia 11:216-226, 2005.
- Arnold DM, Webert KE, Carruthers J, Almonte T, Decker K,
Seroski W. Reed J. Chan AKC, Pai M, Walker I.. Trends in the
utilization and wastage of coagulation factor concentrates: the
application of a regional tracking programme. Haemophilia
13:3
271, 2007.
- Association of Hemophilia Clinic Directors of Canada. Causes
of Death in Canadians with Hemophilia 1980-95. Hemophilia 1998;4:714-20
- Barnes C, Rivard GE, Poon MC, Teitel J, Pai M, Kern M,
Blanchette VS, Carcao M; Inhibitor Subcommittee of Association of
Hemophilia Clinic Directors of Canada. Canadian multi-institutional
survey of immune tolerance therapy (ITT) - experience with the use of
recombinant factor VIII for ITT. Haemophilia. 2006
Jan;12(1):1-6.
- Barr RD, Sek J, Horsman J, Furlong W, Saleh M, Pai M,
Walker IR. Health Status and Health-Related Quality of Life
Associated with von Willebrand Disease. American Journal of
Hematology 73:108-114, 2003.
- Blanchette V, Rivard G, Israels S, Robinson S,
Ali
K, Walker I, Stain A.M, and Blanchette V, on behalf of the Association
of Hemophilia Clinic Directors of Canada and the Canadian Association
of Nurses in Hemophilia Care. A survey of factor prophylaxis in the
Canadian haemophilia A population. Hemophilia
(2004), 10, 679–68
- Blanchette V, Walker I, Gill P, Adams M, Roberts R, Inwood
M, Canadian Hemophilia Clinic Directors Group. Hepatitis
C Infection in Patients with Hemophilia. Results of a National Survey.
Transfusion Medicine Reviews. 1994;8:210-217.
- Canadian Hemophilia Clinic Directors Group. Effect
of using safer blood products on prevalence of HIV infection in
haemophilic Canadians. Brit Med J 306: 306-7, 1993.
- Carcao M, St Louis J, Poon MC, Grunebaum E, Lacroix S,
Stain AM, Blanchette VS, Rivard GE; Inhibitor Subcommittee of
Association of Hemophilia Clinic Directors of Canada. Rituximab for
congenital haemophiliacs with inhibitors: a Canadian experience.
Haemophilia. 2006 Jan;12(1):7-18.
- Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers
C, Robinson S, Luke KH, Wu JK, Gill K, Lillicrap D, Babyn P, McLimont
M, Blanchette VS; Association of Hemophilia Clinic Directors of Canada
Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A:
interim results from the first 5 years of the Canadian Hemophilia
Primary Prophylaxis Study. J Thromb Haemost. 2006 Jun;4(6):1228-36.
- Giles AR, Rivard GE, Teitel J, Walker I. Surveillance
for factor VIII inhibitor development in the Canadian hemophilia
population following the widespread introduction of recombinant factor
VIII replacement therapy. Transfus Sci 1998; 19:139-147
- Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I and
the Association of Hemophilia Centre Directors of Canada on behalf of
the SSC Scientific Subcommittee on Factor VIII and Factor IX.A
Detailed Comparison of the Performance of the Standard versus the
Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C
Inhibitors in the Haemophilia A Population of Canada. Vol. 79(4), page 872.
- James P, Lillicrap D. Genetic testing for von Willebrand
disease: the Canadian experience. Semin Thromb Hemost. 2006
Jul;32(5):546-52.
- James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin
S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brien L, Othman M,
Rivard G, Rapson D, Hough C, Lillicrap D. The mutational spectrum of
type 1 von Willebrand disease: Results from a Canadian cohort study.
Blood. 2007 Jan 1;109(1):145-54.
- James PD, Paterson AD, Notley C, Cameron C, Hegadorn C,
Tinlin S, Brown C, O'Brien L, Leggo J, Lillicrap D; ASSOCIATION OF
HEMOPHILIA CLINIC DIRECTORS OF CANADA. Genetic linkage and association
analysis in type 1 von Willebrand disease: results from the Canadian
type 1 VWD study. J Thromb Haemost. 2006 Apr;4(4):783-92.
- Lane SJ, Heddle NM, Arnold E, Walker I. A review of
randomized controlled trials comparing the effectiveness of hand held
computers with paper methods for data collection. BMC Medical
Informatics and Decision Making, 6:23, 2006.
- O'Brien LA, James PD, Othman M, Berber E, Cameron C,
Notley CR, Hegadorn CA, Sutherland JJ, Hough C, Rivard GE, O'Shaunessey
D, Lillicrap D; Association of Hemophilia Clinic Directors of Canada.
Founder von Willebrand factor haplotype associated with type 1 von
Willebrand disease. Blood. 2003 Jul 15;102(2):549-57.
- Ota S, Mclimont M, Carcao MD, Blanchette VS, Graham N,
Paradis E, Feldman BM. Definitions for haemophilia
prophylaxis
and its outcomes: the Canadian consensus study. Haemophilia. 2007
Jan;13(1):12-20.
- James, PD, Notley C, Hegadorn C, Poon MC, Walker I, Rapson D,
Association of Hemophilia Clinic Directors of Canada, Lillicrap D; Challenges in defining type 2M von Willebrand disease: resutls from a Canadian cohort study. Journal of Thrombosis and Haemostasis 2007; 5: 1914-1922.
- Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant
Factor IX Recovery and Inhibitor Safety: A Canadian Post-Licensure
Surveillance Study. Thromb Haemost 2002; 87: 431-435
- Rubinger M, Lillicrap D, Rivarg GE, Teitel J, Carcao M, Hensman C, Walker I and the Association of Hemophilia Clinic Directors of Canada: A Prospective Surveillance Study of Factor VIII Inhibitor Development in the Canadian Hemophilia A Population Following the Switch to a Recombinant Factor VIII Product formulated with Sucrose. Haemophilia 2008.
- Rubinger M, Rivard GE, Teitel J, Walker I. Suggestions
for the management of factor VIII inhibitors. Haemophilia 2000, Suppl.1:52-9.
- Teitel JM, Card R, Strawczynski H, and the Association of
Hemophilia Clinic Directors of Canada. Laboratory
and Clinical Markers of HIV Infection in Canadian Hemophiliacs after
Two Years Treatment with Recombinant Factor VIII Concentrate.
Haemophilia, 4:731-738, 1998.
- Walker I.R, Sek J.T, Almonte T.M, Carruthers J.B, Chan
A.K.C, Pai M.K, Thibault A. T, and Heddle N.M. Developing
a tracking system for coagulation factor concentrates in souther
Ontario. Transfusion Volume 43, May 2003, page 556-562.
- Walker I. Survey of the Canadian Hemophilia
Population. Can J Public Health 1991;82:127 129
- Walker I et al. The Canadian Hemophilia
Registry as the Basis for a National System for Monitoring the Use of
Factor Concentrates. Accepted for Transfusion, July 1995
- Walker I, Sigouin C, Sek J, Almonte T, Carruthers J, Chan
A, Pai M, Heddle N., Comparing hand-held computers and paper diaries
for haemophilia home therapy: A randomized trial. Haemophilia
10,
1-7, 2004.
- Walker I, Poon MC. Recombinant factor VIII concentrate.
The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic
Directors Group. Lancet.1992; 339:61-2.
- Webert KE, Arnold DM, Carruthers J, Molnar L, Amonte T, Decker K, Seroki W, Reed J, Chan A, Pai M and Walker IR. Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and withouth haemophilia. Haemophilia 2007; 13, 528-526.
- Young NL, Bradley CS, Wakefield CD, Barnard D, Blanchette
VS, McCusker PJ. How well does the Canadian Haemophilia Outcomes-Kids'
Life Assessment Tool (CHO-KLAT) measure the quality of life of boys
with haemophilia? Pediatr Blood Cancer. 2006 Sep;47(3):305-11.
- Young NL, Bradley CS, Blanchette V, Wakefield CD, Barnard D, Wu JK, McCusker PJ. Development of a health-related quality of life measure for boys with haemophilia: the Canadian Haemophilia Outcomes--Kids Life Assessment Tool (CHO-KLAT). Haemophilia. 2004;10 Suppl 1:34-43.
MEETING ABSTRACTS
- Walker
I, Canadian Hemophilia Clinic Directors Group. Enumeration of the
Canadian Hemophilia Population. XIX International Congress of The World
Federation of Hemophilia 1990, Washington, DC. Book of Abstracts p.45,
1990.
- Walker
IR, Canadian Hemophilia Clinic Directors Group. HIV in Canadians with
Hemophilia: Prevalence, Mortality and the Impact of Safer Factor
Concentrates. XX Congress of the World Federation of Hemophilia,
Athens, Greece, October 1992.
- Blanchette
VS, Walker 1, Inwood M, Adams M, Gill P and the Canadian Hemophilia
Clinic Directors Group. Prevalence of Hepatitis C infection in
individuals with Hemophilia: Results of a National Study. XX Congress
of the World Federation of Hemophilia, Athens, Greece, October 1992.
- Walker
IR, and the Canadian Hemophilia Clinical Directors Group. Canadian
Hemophilia Registry (CHR) - Update and Assessment of Completeness. XXI
International Congress of the World Federation of Hemophilia, Mexico
City, Mexico. April 1994.
- Inwood
MJ, Clegg E, Carter S. on behalf of the Canadian Hemophilia Centre
Directors and Nurse Coordinators Group. A survey of Central Venous
Access Devices (CVAD) in a Canadian Hemophilia Population. Presented at
the congress of the World Hemophilia Federation, Mexico City, April
24-9, 1994.
- Inwood
MJ, Clegg E, Carter S. on behalf of the Canadian Hemophilia Centre
Directors and Nurse Coordinators Group. A survey of Pyoarthrosis in a
Canadian Hemophilia Population. Presented at the congress of the World
Hemophilia Federation, Mexico City, April 24-9, 1994.
- Walker
I, Association of Hemophilia Clinic Directors of Canada. Liver Disease
in Hemophilia: New Directions in Diagnosis, Management and Treatment.
National Hemophilia Foundation. Atlanta, Georgia, March 3-5, 1995.
- Walker
I, Julian J, Association of Hemophilia Clinic Directors of Canada.
Causes of Death in Canadians with Hemophilia 1980-1995. XXII Congress
of the World Federation of Hemophilia, Dublin, Ireland, May 1996.
- Lee DH, Walker IR, Poon MC, Rivard G, Teitel J, Ritchie B, Akabutu J, Sinclair GD, Pai M, Wu J, Reddy S, Crowther MA, Blachman MA. Factor V Leiden Is Not Protective in Severe Hemophilia. Hemophilia 1996;2 supp 1:178.
ahcdc major award recipients
2007
- Dr. David Lillicrap - ISTH Bi-Annual
Investigator Recognition Award
- Dr. Paula James - Bayer Hemophilia Awards Program - Early Career Investigator Award
- Dr. Shannon Meeks - Bayer Health Awards Program - Clinical Training Fellowship Award
- Dr. Melanie Bodnar - AHCDC - Bayer Fellowship in Hemostasis